Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) recorded a trading volume of 0.54 million shares, above its 90-day volume average of 0.22 million shares. The stock kicked off the session at $1.65 and later approached $1.58 with a change of -12.5%.Titan Pharmaceuticals, Inc. (TTNP) Analyst Opinion
Titan Pharmaceuticals, Inc. has a consensus outperform rating from 1 Wall Street analysts, and the number of shares currently sold short amount to at least 5.06% of shares outstanding. The stock sank -30% last month and is down -60.62 this year. Wall Street is only getting more bullish on the stock, with 1 of analysts who cover TTNP having a buy-equivalent rating. Analysts have placed a $6 price target on Titan Pharmaceuticals, Inc., suggesting a 279.75% gain from recent close. It’s currently trading about -67.19% below its 52-week high.Titan Pharmaceuticals, Inc. Earnings Surprise
Titan Pharmaceuticals, Inc. (TTNP) failed to surprise the stock market in its last reported earnings when it earned -$0.17 a piece versus the consensus-estimated -$0.15. Its revenue totaled $100000 up 150% from the previous quarter.Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Intraday View
This stock (TTNP) is ahead of its 52-week low with 21.15%. Its last month’s stock price volatility remained 8.69% which for the week stands at 10.92%. The share price has moved backward from its 20 days moving average, trading at a distance of -21.59% and stays -14.68% away from its 50 days moving average. Over the last five days, shares have faced -19.23% losses and now is down -37.15% since hitting its 200-day moving average of $2.029. Titan Pharmaceuticals, Inc. (TTNP) has made its way to a 12-month decline of -65%.
Turning to Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), its shares were trading at $1.86 a gain of $0.23, on the trading floor. The stock, after opening at $1.6, touched a high of $1.92 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.6. Anthera Pharmaceuticals, Inc. has 0 buy ratings, 3 holds and 0 sells even after the stock tumbled -91.73% from its high of $22.48 to a $19.44 million market value through last close.Anthera Pharmaceuticals, Inc. (ANTH) Consensus Price Target
The company’s consensus rating on Reuter’s scale remained unchanged from 2.6 to 2.6 during a month. Analysts set a 12-month price target of $6.75 a share. The target implies a 262.9% spike from where the shares are currently trading. Also, the current price highlights a discount of 115.05% to analysts’ high consensus price target.Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Intraday Trading
The counter witnessed a trading volume of 1.06 million shares versus an average volume of 0.44 million shares during last trading session. Its last month’s stock price volatility remained 13.7% which for the week approaches 10.02%. The lowest price the stock reached in the last trading day was $1.581 and compares with the $1.20 52-week low. The stock recovered 55% since its low point and has performed -64.18% year-to-date.